A practical reference on melanocortin receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-10. Anything still debated is marked as such rather than presented as settled.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Methylthioninium chloride, commonly called methylene blue, is a salt used as a dye and as a medication. As a medication, it is mainly used to treat methemoglobinemia. It has previously been used for treating cyanide poisoning and urinary tract infections, but this use is no longer recommended. It has also been used to treat cases of malaria for over a century. Methylene blue is typically given by injection into a vein. Common side effects include headache, nausea, and vomiting. Methylene blue was first prepared in 1876, by Heinrich Caro. It is on the World Health Organization's List of Essential Medicines. In recent years, methylene blue has been promoted for various health effects, but outside its established medical use, its safety and effectiveness are unproven; it is potentially toxic and should only be used under a doctor's prescription.
The club's reserve team, formerly the SC Freiburg Amateure, now SC Freiburg II, has, for the most part of its history played in the lower amateur leagues. It made a three-season appearance in the tier four Verbandsliga Südbaden from 1983 to 1986, but then took until 1994 to return to this league. In 1998 the team won promotion to the Oberliga Baden-Württemberg after a league championship in the Verbandsliga. Freiburg II spent the next ten seasons at this level as an upper table side before another league championship took the team to the Regionalliga Süd. After four seasons at this league the team became part of the new Regionalliga Südwest in 2012. After a seventh place in its first season in the league the team finished runner-up in 2013–14. A South Baden Cup win in 2001 qualified it for the first round of the 2001–02 DFB-Pokal, the German Cup, where it lost to Schalke 04.
In Japan, indigo became especially important during the Edo period. This was due to a growing textiles industry, and because commoners had been banned from wearing silk, leading to the increasing cultivation of cotton, and consequently indigo – one of the few substances that could dye it. In North America, indigo was introduced into colonial South Carolina by Eliza Lucas, where it became the colony's second-most important cash crop (after rice). As a major export crop, indigo supported plantation slavery there. In the May and June 1755 issues of The Gentleman's Magazine, there appeared a detailed account of the cultivation of indigo, accompanied by drawings of necessary equipment and a prospective budget for starting such an operation, authored by South Carolina planter Charles Woodmason. It later appeared as a book. By 1775, indigo production in South Carolina exceeded 1,222,000 pounds. When Benjamin Franklin sailed to France in November 1776 to enlist France's support for the American Revolutionary War, 35 barrels of indigo were on board the Reprisal, the sale of which would help fund the war effort. In colonial North America, three commercially important species are found: the native I. caroliniana, and the introduced I. tinctoria and I. suffruticosa. In the UK the structure of Natural Indigo was still being sought in 1878 when Edward Schunck published on Indigo e.g. Blue from Polygonum tinctorium and By other Plants (16 April 1878) to the Manchester Literary and Philosophical Society
Sources: en.wikipedia.org
2 H2O2 → 2 H2O + O2 The rate of decomposition increases with rise in temperature, concentration, and pH. H2O2 is unstable under alkaline conditions. Decomposition is catalysed by various redox-active ions or compounds, including most transition metals and their compounds (e.g. manganese dioxide (MnO2), silver, and platinum).
=== Presence in livestock species during gestation === Bovine/Ovine RBP, identical to that found in plasma has been identified in the placental tissues of both the ovine and the bovine, suggesting that RBP may be highly involved in retinol transport and metabolism during pregnancy. However, exact timing of expression had been yet to be identified. An antiserum specific for bovine conceptus RBP and immunohistochemistry has been utilized to identify the presence of RBP at different stages of early pregnancy. Strong immunostaining and hybridization were observed in the trophectoderm of tubular, but not spherical blastocysts at day 13. RBP mRNA was localized to epithelial cells of the chorion, allantois, and amnion at day 45 of pregnancy. Lastly, RBP mRNA was detected in the cotyledons, the fetal contribution to the placenta and the site of attachment to the uterine epithelium for fetal/maternal exchange. Expression of RBP in developing conceptuses, extraembryonic membranes, and at the fetal-maternal interface indicate that there may be some regulation of retinol transport and metabolism that occurs due to RBP by the extraembryonic membranes. Within the uterus of pregnant bovines, it has been found that RBP synthesis in the luminal and glandular epithelium is quite similar to that of a cyclic animal's; however upon reaching day 17 of the estrous cycle, levels of RBP remain constant and continue to gradually rise throughout gestation. It has also been suggested that ovarian steroids may play a role in regulating uterine RBP expression.
Since its inception in 1988, the program has trained numerous scientists who have established successful research careers and obtained competitive NIH fellowships, career development awards, and independent research grants. The continued success of its alumni reflects the program's commitment to scientific excellence, mentorship, collaborative research, and the development of future leaders dedicated to advancing the biology of aging and translating discoveries into interventions that extend healthy lifespan.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.